MZB1 and plasma cell myeloma: Except for cases of leukemia, lymphoma and myeloma where elevated levels of MZB1 may be linked to abnormalities in B cell proliferation, survival and differentiation, altered expression of MZB1 is likely to be a byproduct of passenger mutations in most types of cancer.